Nonobstructive CAD: Recognition needed, treatment options sought
Bococizumab reduces LDL in patients with hypercholesterolemia
Lipid Forum II Highlights
Antiplatelet Therapy in ACS and PCI
VIENNA — Cardiovascular risks increased with rising severity of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and cirrhosis, according to a study presented at the 2015 International Liver Congress.
“We have shown a trend towards increasing mortality and increasing association of cardiovascular comorbidities as you move across the NAFLD spectrum,” Jake Mann, MD, of the University of Cambridge, said during a press conference.
This activity is supported by an educational grant from AstraZeneca.
This activity is supported by an educational grant from Eisai, Inc. and Vivus, Inc.
The role of lipid-lowering therapies: A look at the guidelines
Nathaniel Reichek, MD: A pioneer in the development of cardiac MRI
This feature offers timely executive summaries of the most relevant journals in cardiology.
Snapshot summaries of recent study results in cardiology.
Your central portal for information presented at ACC 2015.
Your resource for news and videos from SCAI 2014.
This exclusive Healio resource provides you a comprehensive window into what your colleagues and key opinion leaders are saying about current and future drugs and devices and their impact on patient outcomes.
Related story »
View past polls »
Search Healio's robust listing of national and international medical meetings.
©2015 All Rights Reserved.